Hims & Hers Health, Inc. (HIMS) shares soared 41.88 percent to $22.33, up $6.59 on Monday, after the company announced a collaboration with Novo Nordisk to expand access to FDA-approved GLP-1 weight-loss treatments on its platform.
The stock is currently trading at $22.33, up from its previous close of $15.74. Shares opened at $23.22 and traded between $20.97 and $23.51 during the session on the New York Stock Exchange. Trading volume surged to 106.58 million shares, far exceeding its average volume of 23.56 million shares.
Under the agreement, Hims & Hers plans to offer access to Novo Nordisk's semaglutide-based treatments, including Ozempic and Wegovy, while gradually shifting customers toward FDA-approved GLP-1 medications rather than compounded versions.
The stock has traded in a 52-week range of $13.74 to $70.43.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.